menu
    • menu
    [{"orgOrder":0,"company":"myNEO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CAMYO-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"myNEO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"myNEO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"myNEO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bisantrene DiHCl","moa":"FTO protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ Race Oncology"},{"orgOrder":0,"company":"Cellistic","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"BP2202","moa":"BCMA receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellistic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellistic \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellistic \/ BrightPath Biotherapeutics"},{"orgOrder":0,"company":"ATB Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ATB Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATB Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"ATB Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"4","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Complix","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ I-Mab Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Complix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MCL1","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ Inapplicable"},{"orgOrder":0,"company":"Ncardia","sponsor":"Kiniciti","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ncardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ncardia \/ Kiniciti","highestDevelopmentStatusID":"4","companyTruncated":"Ncardia \/ Kiniciti"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellistic

                            Belgium arrow
                            EPS
                            Not Confirmed

                            Cellistic

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP2202

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BrightPath Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BrightPath, Cellistic Collaborate on BCMA CAR-iNKT Cell Phase 1 Trial

                            Details : The collaboration aims to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials.

                            Product Name : BP2202

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 13, 2024

                            Lead Product(s) : BP2202

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BrightPath Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATB Therapeutics

                            Belgium arrow
                            EPS
                            Not Confirmed

                            ATB Therapeutics

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : EQT Life Sciences

                            Deal Size : $56.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            EQT Life Sciences Leads €54 Million Series A Financing of ATB Therapeutics

                            Details : The proceeds will fund development of oncology and immunology therapeutics derived from innovative antibody payload platform, including novel antibody therapies for oncology and auto-immune disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : EQT Life Sciences

                            Deal Size : $56.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ardena

                            Belgium arrow
                            EPS
                            Not Confirmed

                            Ardena

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bisantrene DiHCl

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Race Oncology

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220

                            Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).

                            Product Name : RC220

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Bisantrene DiHCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Race Oncology

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            myNEO Therapeutics

                            Belgium arrow
                            EPS
                            Not Confirmed

                            myNEO Therapeutics

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAMYO-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            myNEO Evolves into myNEO Therapeutics to Reflect its New Strategy to Develop off-the-shelf Cancer Vaccine Immu...

                            Details : CAMYO-01 is a novel off-the-shelf cancer vaccine, which is incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.

                            Product Name : CAMYO-01

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 25, 2023

                            Lead Product(s) : CAMYO-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celyad

                            Belgium arrow
                            EPS
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Fortress Investment Group

                            Deal Size : $10.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments from Historical Shareholders

                            Details : The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA techn...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 24, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Fortress Investment Group

                            Deal Size : $10.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ncardia

                            Belgium arrow
                            EPS
                            Not Confirmed

                            Ncardia

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Kiniciti

                            Deal Size : $60.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings

                            Details : The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Kiniciti

                            Deal Size : $60.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Complix

                            Belgium arrow
                            EPS
                            Not Confirmed

                            Complix

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : I-Mab Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Complix Signs Agreement with I-Mab to Develop Cell Penetrating Alphabodies against 2 Intracellular Immuno-onco...

                            Details : Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 03, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : I-Mab Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Complix

                            Belgium arrow
                            EPS
                            Not Confirmed

                            Complix

                            Belgium arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances

                            Details : The proof-of-concept study showed the potential of Cell-Penetrating Alphabodies to efficiently penetrate the cancer cell membrane, disrupt an intracellular protein-protein interface, and cause an anti-tumor effect upon in vivo administration in relevant ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 31, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth